David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line Follicular Lymphoma

Thursday, June 18, 2015

With median progression-free survival reaching seven years in first-line follicular lymphoma patients, evaluating new treatments is difficult. Daniel Sargent, PhD, describes an easier-to-assess, accurate endpoint.

July 2018, Volume 4, Issue 8

June 2018, Volume 4, Issue 7

May 2018, Volume 4, Issue 6

Focus on Myeloid Malignancies (Volume 4, Issue 6.1)

David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line Follicular Lymphoma

Recent Articles

MD Anderson Fined $4.3 Million for HIPAA Violation

CMS Cancels Agreement With Novartis to Pay for CAR T-Cell Treatment

Shortages Are Forcing Physicians and Pharmacists to Ration Opioids

EMA Recommends CAR T-Cell Therapies for Approval

Travel Ban Ruling Disappoints Medical Community

Current Issue

July 2018, Volume 4, Issue 8

Meeting Coverage

CPX-351 Outperforms Induction Chemotherapy in Older High-Risk Patients With AML

Durable Response Observed With Pracinostat and Azacitidine for Older Patients With AML

Editor`s Corner

Burnout? What Burnout?

Tiny Bubbles